Comparison
While CJC-1295 is used in research to chronically elevate endogenous growth hormone and IGF-1 levels, enabling studies of body composition, metabolic, and anti-aging effects of prolonged GH exposure10, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While CJC-1295 works as a tetrasubstituted 29-amino-acid analog of GHRH(1–29) that acts as a potent agonist at the GHRH receptor and, in its DAC form, covalently binds serum albumin to extend half-life from minutes to days, resulting in sustained pulsatile GH and IGF-1 increase1082, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
CJC-1295 is 29 amino acids long, whereas Liraglutide is longer as it has a length of 31 amino acids. CJC-1295 is made up of a sequence of Tyrosine, Alanine, Aspartic acid, Alanine, Isoleucine, Phenylalanine, Threonine, Glutamine, Serine, Tyrosine, Arginine, Lysine, Valine, Leucine, Alanine, Glutamine, Leucine, Serine, Alanine, Arginine, Lysine, Leucine, Leucine, Glutamine, Aspartic acid, Isoleucine, Leucine, Serine, Arginine. Liraglutide is made up of a sequence of sequence data not available in the current dataset.
CJC-1295
GHRH
Liraglutide
GCG